JP2017503481A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017503481A5 JP2017503481A5 JP2016536527A JP2016536527A JP2017503481A5 JP 2017503481 A5 JP2017503481 A5 JP 2017503481A5 JP 2016536527 A JP2016536527 A JP 2016536527A JP 2016536527 A JP2016536527 A JP 2016536527A JP 2017503481 A5 JP2017503481 A5 JP 2017503481A5
- Authority
- JP
- Japan
- Prior art keywords
- dlbcl
- lenalidomide
- patient
- pharmaceutically acceptable
- isomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361913046P | 2013-12-06 | 2013-12-06 | |
| US61/913,046 | 2013-12-06 | ||
| PCT/US2014/068767 WO2015085160A2 (en) | 2013-12-06 | 2014-12-05 | Methods for treating hematological cancers and the use of biomarkers as a predictor of clinical sensitivity to immunodulatory therapies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017503481A JP2017503481A (ja) | 2017-02-02 |
| JP2017503481A5 true JP2017503481A5 (enExample) | 2018-01-18 |
Family
ID=53274284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536527A Pending JP2017503481A (ja) | 2013-12-06 | 2014-12-05 | 血液癌を治療する方法及び免疫調節療法に対する臨床的感受性の予測因子としてのバイオマーカーの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20160312292A1 (enExample) |
| EP (1) | EP3077547A4 (enExample) |
| JP (1) | JP2017503481A (enExample) |
| KR (1) | KR20160090390A (enExample) |
| AU (1) | AU2014360316A1 (enExample) |
| BR (1) | BR112016012792A2 (enExample) |
| CA (1) | CA2932266A1 (enExample) |
| EA (1) | EA201691143A1 (enExample) |
| IL (1) | IL245936A0 (enExample) |
| MX (1) | MX2016007179A (enExample) |
| PH (1) | PH12016501023A1 (enExample) |
| WO (1) | WO2015085160A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015077058A2 (en) | 2013-11-08 | 2015-05-28 | The Broad Institute, Inc. | Compositions and methods for selecting a treatment for b-cell neoplasias |
| BR112016012795A2 (pt) | 2013-12-06 | 2017-08-08 | Celgene Corp | Métodos para a determinação da eficácia do fármaco para o tratamento de linfoma difuso de grandes células b, mieloma múltiplo e cânceres mieloides |
| WO2016060557A1 (en) * | 2014-10-17 | 2016-04-21 | Stichting Maastricht Radiation Oncology "Maastro-Clinic" | Image analysis method supporting illness development prediction for a neoplasm in a human or animal body |
| WO2016196580A1 (en) | 2015-06-02 | 2016-12-08 | Celgene Corporation | Methods for determining drug efficacy for treatment of cancer using ratios of cereblon associated proteins |
| EP3347717A4 (en) | 2015-09-11 | 2019-06-05 | The Brigham and Women's Hospital, Inc. | PROCESS FOR CHARACTERIZING THE RESISTANCE TO CEREBLON MODULATORS |
| CA2999179A1 (en) * | 2015-09-25 | 2017-03-30 | Celgene Corporation | Methods for treating diffuse large b-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs |
| WO2017120446A1 (en) | 2016-01-08 | 2017-07-13 | Celgene Corporation | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies |
| US20200270703A1 (en) * | 2017-09-29 | 2020-08-27 | Kyushu University, National University Corporation | Method and kit for predicting therapeutic effectiveness of chemotherapy for diffuse large b-cell lymphoma patients |
| MX2022004688A (es) * | 2019-10-21 | 2022-05-10 | Celgene Corp | Métodos para tratar un cáncer hematológico y uso de biomarcadores compañeros para 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-mor folinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona. |
| WO2024258819A1 (en) * | 2023-06-15 | 2024-12-19 | The Broad Institute, Inc. | Neoplastic cytotoxicity induced by glycosylation |
| FR3158744A1 (fr) * | 2024-01-30 | 2025-08-01 | Universite Grenoble Alpes | Biomarqueurs et outil pronostique pour les patients atteint de lymphomes b diffus a grandes cellules |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7964354B2 (en) * | 2007-12-20 | 2011-06-21 | Celgene Corporation | Use of micro-RNA as a biomarker of immunomodulatory drug activity |
| EP2544687A1 (en) * | 2010-03-12 | 2013-01-16 | Celgene Corporation | Methods for the treatment of non-hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor |
| MX353482B (es) * | 2011-04-29 | 2018-01-16 | Celgene Corp | Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor. |
-
2014
- 2014-12-05 WO PCT/US2014/068767 patent/WO2015085160A2/en not_active Ceased
- 2014-12-05 CA CA2932266A patent/CA2932266A1/en not_active Abandoned
- 2014-12-05 JP JP2016536527A patent/JP2017503481A/ja active Pending
- 2014-12-05 KR KR1020167017539A patent/KR20160090390A/ko not_active Withdrawn
- 2014-12-05 EA EA201691143A patent/EA201691143A1/ru unknown
- 2014-12-05 MX MX2016007179A patent/MX2016007179A/es unknown
- 2014-12-05 EP EP14867978.0A patent/EP3077547A4/en not_active Withdrawn
- 2014-12-05 US US15/101,866 patent/US20160312292A1/en not_active Abandoned
- 2014-12-05 BR BR112016012792A patent/BR112016012792A2/pt not_active Application Discontinuation
- 2014-12-05 AU AU2014360316A patent/AU2014360316A1/en not_active Abandoned
-
2016
- 2016-05-31 IL IL245936A patent/IL245936A0/en unknown
- 2016-05-31 PH PH12016501023A patent/PH12016501023A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017503481A5 (enExample) | ||
| JP2016500110A5 (enExample) | ||
| RU2015125575A (ru) | Композиции и способы для лечения злокачественной опухоли | |
| Tan et al. | Identification of circulating long non-coding RNA GAS5 as a potential biomarker for non-small cell lung cancer diagnosisnon-small cell lung cancer, long non-coding RNA, plasma, GAS5, biomarker | |
| BR112017025254A2 (pt) | ?métodos para detecção de pelo menos uma mutação em uma pluralidade de genes relacionados ao câncer, selecionar um indivíduo para tratamento e prever a probabilidade de capacidade de resposta ao tratamento? | |
| JO3681B1 (ar) | استخدام مجموعات الجين الطافر fgfr في الكشف عن مرضى السرطان الذين سوف يستجيبون للعلاج بمثبط fgfr | |
| JP2016537010A5 (enExample) | ||
| JP2016536303A5 (enExample) | ||
| Zhang et al. | The expression of Toll-like receptor 8 and its relationship with VEGF and Bcl-2 in cervical cancer | |
| WO2018007872A9 (en) | Biomarkers for inflammatory bowel disease | |
| JP2016501013A5 (enExample) | ||
| Kim et al. | OCT-1, ABCB1, and ABCG2 expression in imatinib-resistant chronic myeloid leukemia treated with dasatinib or nilotinib | |
| Chen et al. | CCL22 and IL-37 inhibit the proliferation and epithelial-mesenchymal transition process of NSCLC A549 cells | |
| Chen et al. | Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel | |
| JP2016510591A5 (enExample) | ||
| JP2016540726A5 (enExample) | ||
| Wang et al. | Effects of miR-455 on PIK3R1 gene expression regulation and kidney cancer cell functions. | |
| JP2015517500A5 (enExample) | ||
| Deshmukh et al. | Genomic profiling of cell lines for personalized targeted therapy for hepatocellular carcinoma | |
| WO2023023592A1 (en) | Repurposing drugs for non-small cell lung cancer | |
| Bialopiotrowicz et al. | Microenvironment-induced expression of PIM kinases supports chronic lymphocytic leukemia cells survival and promotes CXCR4-mTOR pathway dependent migration | |
| Liu et al. | Investigation of the feasibility of NRAV as a biomarker for hepatocellular carcinoma | |
| An et al. | Lower Ras expression as an independent predictor of patient outcomes in lung cancer treated with bevacizumab plus chemotherapy | |
| Lee et al. | Determining the effect of transforming growth factor-β1 on cdk4 and p27 in gastric cancer and cholangiocarcinoma | |
| Deig et al. | Blood-based nucleic acid biomarkers as a potential tool to determine radiation therapy response in non-small cell lung cancer |